Last updated: August 1, 2026
Aldurazyme, or laronidase, is an enzyme replacement therapy approved for mucopolysaccharidosis type I (MPS I). Sanofi’s Genzyme division markets the product in major markets. The therapy has long-term regulatory protection only through its biologic product profile, orphan-drug history and manufacturing complexity; its U.S. orphan exclusivity expired in 2010. No approved U.S. biosimilar or direct generic equivalent has displaced Aldurazyme.
Clinical development is mature. Current research is focused on long-term outcomes, treatment optimization, hematopoietic stem-cell transplantation, intrathecal or gene-based alternatives, and earlier diagnosis rather than a new pivotal Aldurazyme indication. Revenue is likely to remain relatively stable because recurring lifelong treatment supports demand, while small patient populations, high treatment cost and emerging gene therapies constrain volume growth.
What is Aldurazyme and what disease does it treat?
Aldurazyme is recombinant human alpha-L-iduronidase, also known as laronidase. It replaces the deficient lysosomal enzyme in patients with MPS I, a rare autosomal-recessive disorder caused by mutations in the IDUA gene.
MPS I causes accumulation of glycosaminoglycans, particularly dermatan sulfate and heparan sulfate. Clinical manifestations can include:
- Skeletal abnormalities
- Joint stiffness
- Corneal clouding
- Airway disease
- Cardiovascular disease
- Hearing impairment
- Hepatosplenomegaly
- Neurodevelopmental impairment in severe disease
The U.S. label indicates Aldurazyme for patients with MPS I. The standard dosage is 0.58 mg/kg by intravenous infusion once weekly. Infusions may require several hours, and hypersensitivity or infusion-associated reactions are clinically important management issues (U.S. Food and Drug Administration [FDA], 2003).
Aldurazyme product profile
| Attribute |
Details |
| Active ingredient |
Laronidase |
| Enzyme |
Recombinant human alpha-L-iduronidase |
| Therapeutic class |
Lysosomal enzyme replacement therapy |
| Disease |
Mucopolysaccharidosis type I |
| Administration |
Intravenous infusion |
| Standard dose |
0.58 mg/kg weekly |
| U.S. regulatory pathway |
Biologics license application |
| U.S. approval |
2003 |
| U.S. sponsor |
Genzyme, now part of Sanofi |
| Primary competitors |
Hematopoietic stem-cell transplantation, investigational gene therapy and future enzyme or biosimilar products |
What clinical trials established Aldurazyme’s efficacy?
The pivotal U.S. development program included a randomized, double-blind, placebo-controlled study followed by an open-label extension. The trial enrolled patients with MPS I and evaluated urinary glycosaminoglycan reduction, liver volume and functional outcomes.
The principal findings were:
- Reduced urinary glycosaminoglycan levels
- Reduced hepatomegaly
- Improvement in selected pulmonary and functional measures
- No evidence that enzyme replacement reverses established irreversible skeletal or neurologic disease
- Frequent infusion-associated reactions, generally managed through infusion-rate adjustment and medication
The FDA approval relied on biochemical and organ-response measures in a rare-disease population rather than a conventional mortality or long-term disability endpoint. The product’s clinical benefit is strongest when treatment begins before substantial irreversible organ damage.
How does Aldurazyme compare with hematopoietic stem-cell transplantation?
Hematopoietic stem-cell transplantation remains an important treatment option for selected patients with severe MPS I, particularly young children with Hurler syndrome. Transplantation can provide enzyme production from donor-derived cells and may offer better preservation of central nervous system function when performed early.
Aldurazyme has a different clinical role:
| Consideration |
Aldurazyme |
Hematopoietic stem-cell transplantation |
| Administration |
Weekly lifelong infusion |
One-time transplant procedure |
| Neurologic benefit |
Limited for established CNS disease |
Potentially greater if performed early |
| Treatment risk |
Infusion reactions and antibody development |
Graft-versus-host disease, infection and transplant mortality |
| Eligibility |
Broad MPS I population |
Limited by age, disease severity and donor factors |
| Skeletal outcomes |
Limited reversal of established disease |
May slow progression but does not normalize skeletal disease |
| Commercial effect |
Recurring pharmaceutical revenue |
Can reduce long-term enzyme use in transplanted patients |
Clinical practice often uses Aldurazyme before transplantation or in patients who are not transplant candidates. The two approaches are not fully interchangeable.
What is the current Aldurazyme clinical-trial status?
Aldurazyme’s pivotal clinical development is complete. Publicly registered studies have primarily addressed long-term safety, organ outcomes, transplant-related treatment, immunogenicity and alternative delivery approaches.
The current development profile is best characterized as follows:
| Development area |
Status and commercial relevance |
| New pivotal intravenous indication |
No established late-stage program |
| Long-term extension studies |
Support durability and safety data |
| Pediatric treatment |
Important clinical use, particularly before irreversible disease progression |
| Hematopoietic stem-cell transplantation |
Treatment sequencing and outcome research |
| Intrathecal enzyme delivery |
Investigational; intended to address CNS limitations |
| Gene therapy |
Competitive threat rather than an Aldurazyme expansion program |
| Biomarker and newborn-screening studies |
May increase diagnosis and treatment initiation |
| Immunogenicity |
Continues to influence infusion management and response |
ClinicalTrials.gov records for laronidase and MPS I show a mature program with completed or observational studies rather than a broad new registration campaign. Research in MPS I increasingly targets earlier diagnosis, genotype-phenotype relationships, neurodevelopmental outcomes and one-time genetic interventions (ClinicalTrials.gov, 2024).
What are the main limitations of current Aldurazyme trials?
The core limitations are typical of ultra-rare disease development:
- Small patient populations limit statistical power.
- Biochemical endpoints do not always predict long-term functional benefit.
- MPS I is clinically heterogeneous.
- Delayed diagnosis can make irreversible disease difficult to modify.
- Long-term randomized comparisons are difficult to conduct.
- Transplantation and supportive care create confounding treatment effects.
These limitations reduce the probability of a large label expansion based solely on conventional Aldurazyme trials.
What is the FDA regulatory and exclusivity status of Aldurazyme?
The FDA approved Aldurazyme in 2003 under the biologics framework. The product received orphan-drug designation for MPS I. U.S. orphan exclusivity lasted seven years from approval and expired in 2010.
Aldurazyme regulatory timeline
| Date |
Event |
| 2003 |
FDA approval of Aldurazyme |
| 2003-2010 |
U.S. orphan-drug exclusivity period |
| 2003 |
European Union authorization |
| 2010 onward |
Commercial protection depends on biologic competition, manufacturing know-how, contractual barriers and market access |
| Current status |
Approved therapy with no U.S.-approved biosimilar |
Aldurazyme is regulated as a biologic rather than a conventional small-molecule drug. It therefore does not have a traditional Hatch-Waxman generic pathway. A competing product would generally require a biosimilar or interchangeable biosimilar application under the Public Health Service Act, although the practical burden for a complex recombinant enzyme remains substantial.
What is the Orange Book status of Aldurazyme?
Aldurazyme is not expected to have a conventional Orange Book patent-listing profile because biologic products are generally cataloged through the FDA’s Purple Book rather than the Orange Book. The key U.S. regulatory records are:
- Biologics License Application 125118
- FDA-approved prescribing information
- Purple Book reference-product status
- Orphan-drug designation and exclusivity history
Patent expiry analysis based only on Orange Book listings is therefore unsuitable for Aldurazyme.
What patents protect Aldurazyme?
Aldurazyme’s original patent estate was based on recombinant alpha-L-iduronidase, production methods, cell systems, formulations and therapeutic use. Many early platform and product patents would have expired or entered the public domain after more than two decades from their earliest effective filing dates.
The commercially relevant protection today is less likely to be a single blocking composition-of-matter patent and more likely to involve:
- Cell-line and expression technology
- Purification and viral-clearance processes
- Formulation and stability controls
- Manufacturing specifications
- Device and infusion-system know-how
- Trade secrets governing biologic production
- Regulatory exclusivity for any newly approved modification
How strong is the Aldurazyme patent estate?
The estate is commercially durable but legally different from a small-molecule patent estate.
| Protection category |
Current assessment |
| Original active-ingredient patents |
Likely limited by age and expiration |
| Orphan exclusivity |
Expired in the United States |
| Formulation patents |
Potentially relevant but unlikely to block all biosimilar development |
| Manufacturing patents |
More important because process replication is difficult |
| Trade secrets |
High practical value |
| Regulatory reference-product protection |
Remains relevant to biosimilar developers |
| Patent litigation risk |
Lower than for a recently launched small molecule, but not eliminated |
A biosimilar developer could face substantial analytical, clinical and manufacturing costs even without a broad blocking patent. For enzyme replacement therapies, process similarity, glycosylation, activity, uptake and immunogenicity are central technical barriers.
Which companies are challenging Aldurazyme?
No major U.S. biosimilar challenger has established commercial entry against Aldurazyme. Competitive pressure comes primarily from alternative treatment strategies rather than approved substitutes.
Competitive landscape
| Competitor or alternative |
Competitive position |
| Hematopoietic stem-cell transplantation |
Established alternative for selected severe pediatric patients |
| Gene therapy programs |
Potential one-time treatment threat; clinical and regulatory risk remains high |
| Intrathecal enzyme approaches |
Intended to address limited CNS penetration |
| Future laronidase biosimilars |
Possible after technical and commercial validation |
| Supportive care |
Does not replace enzyme therapy but affects treatment value assessments |
The most important long-term threat is not a conventional generic launch. It is a durable gene therapy or other one-time intervention that reduces lifelong enzyme replacement.
What is the market size and revenue exposure for Aldurazyme?
Sanofi does not consistently report Aldurazyme as a standalone revenue line in public financial disclosures. Revenue is generally embedded within broader rare-disease or specialty-care reporting. Public market-research estimates vary widely because they use different assumptions for treated prevalence, net price, geographic mix and patient weight.
Aldurazyme revenue is supported by:
- Lifelong weekly dosing
- High treatment cost per patient
- Limited competition
- Increasing diagnosis through newborn screening
- Continued treatment of non-transplant candidates
- Expansion of care in emerging specialty markets
Revenue is constrained by:
- Very small global patient population
- Weight-based dosing, which increases pediatric-to-adult cost differences
- Transplantation in selected severe cases
- Treatment discontinuation or non-initiation in advanced disease
- Payer scrutiny of ultra-orphan pricing
- Potential gene-therapy substitution
What drives Aldurazyme pricing?
The economic model is based on recurring enzyme replacement. Annual cost varies by country, negotiated discounts, patient weight, infusion setting and payer policy. U.S. list-price economics can reach several hundred thousand dollars per patient annually, while net prices are lower and materially different across markets.
The most useful commercial metric is treated-patient count multiplied by net annual revenue per patient. Because Sanofi does not disclose a standalone Aldurazyme figure, revenue projections should be modeled by scenario rather than presented as an audited product forecast.
What is the Aldurazyme market projection for 2025-2030?
A base-case forecast is for low-single-digit annual growth in nominal global revenue through 2030, with patient-volume growth partly offset by pricing pressure and treatment substitution.
Scenario projection
| Scenario |
2025-2030 revenue trend |
Main assumptions |
| Downside |
Decline of 3%-7% annually |
Gene-therapy adoption, biosimilar entry, transplant substitution and payer pressure |
| Base case |
Growth of 1%-4% annually |
Stable treated population, modest diagnosis growth and limited direct competition |
| Upside |
Growth of 5%-8% annually |
Expanded newborn screening, earlier treatment and increased access in underpenetrated markets |
These are analytical scenario ranges, not company guidance. The base case assumes no rapid global launch of a highly effective gene therapy and no near-term large-scale biosimilar substitution.
Geographic outlook
United States
The U.S. remains the highest-value market because of specialty-drug pricing and established rare-disease infrastructure. Risks include Medicaid and commercial-payer utilization controls, prior authorization, site-of-care shifts and future biosimilar review.
Europe
European sales are shaped by national reimbursement, hospital procurement and health-technology assessment. Price controls are more pronounced than in the United States, but established treatment pathways support market continuity.
Japan and Asia-Pacific
Diagnosis, reimbursement and specialist availability determine growth. Newborn screening and referral-center development could increase treatment rates, although access remains uneven.
Latin America and other emerging markets
Growth potential is higher, but reimbursement constraints and delayed diagnosis limit near-term revenue conversion. Government-funded rare-disease programs can produce episodic procurement rather than stable commercial demand.
What generic entry risks exist for Aldurazyme?
Traditional generic entry risk is low because Aldurazyme is a biologic. Biosimilar entry risk is possible but technically demanding.
A potential biosimilar developer would need to demonstrate:
- High similarity in structure and enzymatic activity
- Comparable glycosylation and cellular uptake
- Acceptable immunogenicity
- Consistent manufacturing controls
- Comparable pharmacokinetic or pharmacodynamic behavior where required
- Adequate clinical evidence under FDA or European Medicines Agency standards
The commercial market is also difficult. A challenger would need specialized manufacturing, a small but concentrated patient base, payer access and physician confidence in switching. These requirements reduce the attractiveness of entry compared with large-volume biologics.
What patent litigation and settlement agreements affect Aldurazyme?
Aldurazyme has not had the high-profile patent litigation pattern associated with major small-molecule blockbusters. The main legal risk is prospective: a biosimilar sponsor could challenge process, formulation or use patents, or litigate after filing a biosimilar application.
No broadly material public settlement agreement establishing a near-term U.S. biosimilar launch has become a central commercial feature of Aldurazyme’s market. Any future settlement would likely depend on:
- The strength and remaining term of process or formulation patents
- FDA approval timing
- Manufacturing readiness
- Market size
- Sanofi’s willingness to license or delay entry
- Pricing and supply terms
How does Aldurazyme compare with other lysosomal enzyme therapies?
| Product |
Active ingredient |
Disease |
Administration |
Main commercial distinction |
| Aldurazyme |
Laronidase |
MPS I |
Weekly IV |
Mature product with recurring lifelong use |
| Elaprase |
Idursulfase |
MPS II |
Weekly IV |
Similar enzyme-replacement model |
| Vimizim |
Elosulfase alfa |
MPS IV A |
Weekly IV |
Skeletal-disease-focused market |
| Naglazyme |
Galsulfase |
MPS VI |
Weekly IV |
Small, specialized patient population |
| Myozyme/Lumizyme |
Alglucosidase alfa |
Pompe disease |
IV |
Larger disease spectrum and distinct dosing |
| Replagal/Fabrazyme |
Agalsidase products |
Fabry disease |
IV |
Established enzyme-replacement competition |
Aldurazyme’s commercial profile is strongest where early diagnosis and long-term infusion adherence are maintained. Its clinical weakness is limited effect on established central nervous system and skeletal disease.
Key Takeaways
- Aldurazyme is an established weekly enzyme replacement therapy for MPS I.
- The FDA approved it in 2003; U.S. orphan exclusivity expired in 2010.
- No approved U.S. biosimilar or generic equivalent currently displaces the product.
- The clinical program is mature, with current research focused on long-term outcomes, treatment sequencing, CNS delivery and alternatives such as gene therapy.
- Manufacturing complexity and a small patient population provide practical protection after the expiry of early patents.
- Base-case global revenue is likely to remain stable to modestly growing through 2030.
- The principal long-term threat is gene therapy or another durable one-time treatment, not conventional generic competition.
- Sanofi’s lack of standalone Aldurazyme revenue disclosure limits product-specific financial benchmarking.
FAQs About Aldurazyme
Is Aldurazyme still FDA approved?
Yes. Aldurazyme remains FDA approved for patients with MPS I.
Is there a generic version of laronidase?
No conventional generic version exists. A future competitor would generally need to pursue a biosimilar pathway.
Does Aldurazyme treat neurological symptoms of MPS I?
Its effect on established central nervous system disease is limited because intravenous enzyme penetration into the brain is restricted.
Can Aldurazyme be stopped after a patient receives a stem-cell transplant?
Treatment decisions after transplantation depend on enzyme activity, transplant success, residual disease and specialist assessment. Aldurazyme is not automatically continued lifelong in every transplanted patient.
What is the biggest future threat to Aldurazyme sales?
A successful gene therapy that produces durable alpha-L-iduronidase activity could reduce demand for lifelong weekly enzyme replacement.
References
-
ClinicalTrials.gov. (2024). Search results for laronidase and mucopolysaccharidosis type I clinical studies. U.S. National Library of Medicine.
-
European Medicines Agency. (2003). Aldurazyme: EPAR product information. European Medicines Agency.
-
Sanofi. (2024). Annual report 2023. Sanofi.
-
U.S. Food and Drug Administration. (2003). Aldurazyme (laronidase) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
Muenzer, J., Wraith, J. E., Beck, M., Giugliani, R., Harmatz, P., Eng, C. M., Vellodi, A., Martin, R., Ramaswami, U., Gucsavas-Calikoglu, M., McGill, J. J., Kakkis, E. D., Vockley, G., & Childs, R. A. (2009). A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II. Genetics in Medicine, 11(8), 558-567.
-
Wraith, J. E., Clarke, L. A., Beck, M., Kol Podskarbi, T., Pastores, G. M., Muenzer, J., Rapoport, D. M., Berger, K. I., Swiedler, S. J., Kakkis, E. D., & Braakman, T. (2004). Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase. The Journal of Pediatrics, 144(5), 581-588.
